Kaiser Permanente Data Provides Strong Evidence for Continued Value of Combined Pap...

Kaiser Permanente Data Provides Strong Evidence for Continued Value of
Combined Pap and HPV Testing

Evaluation of 800,000 Pap and HPV cotests concludes that "concerns about
excessive HPV test positives...are not borne out"

VENLO, The Netherlands, March 24 /PRNewswire/ -- Physicians from Kaiser
Permanente and the National Cancer Institute report in the March issue of
Obstetrics & Gynecology that results from an evaluation of more than 800,000
Pap and HPV tests conducted at Northern California Kaiser Permanente dispel
the notion that excessive numbers of women would require increased
surveillance and follow-up when HPV testing is implemented. Cervical cancer is
a preventable cancer with a primary known cause -- the human papillomavirus
(HPV). QIAGEN developed and markets the digene(R) HPV Test, a cervical cancer
screening test that detects the high-risk types of HPV that cause cervical
cancer and identify women most at risk for developing the disease.

In the study "Five-Year Experience of Human Papillomavirus DNA and
Papanicolaou Test Cotesting," Dr. Philip E. Castle of the National Cancer
Institute, together with Dr. Walter Kinney of Kaiser Permanente and a team of
other contributors, focused on the early results of combining HPV and Pap
testing for routine cervical cancer screening. Kaiser exclusively used
QIAGEN's Hybrid Capture(R) 2 High-Risk HPV DNA Test for its HPV detection in
the study (also called the digene HPV Test) and conventional cytology for its
Pap testing.

The physicians reported that 90.8 percent of the 580,000 women aged 30 and
older had "double-negative" results, meaning their Paps were normal and they
did not have high-risk types of HPV so were at low risk for developing
cervical cancer. Overall, 6.27 percent of cotests were carcinogenic HPV
positive, and 2.28 percent showed carcinogenic HPV infection together with Pap
results showing pre-cancerous cell changes or inconclusive results. Only 3.99
percent were found HPV-positive with a normal Pap result. Under Kaiser's
previously published protocol, this group of women would be scheduled for
re-testing in 12 months to monitor the persistence of HPV infection. The study
authors concluded, "In a general screening population, concerns about
excessive HPV test positives among women aged 30 years and older are not borne
out."

Investigators also revealed that among those women who tested positive for
high-risk HPV infection with the digene HPV Test, patients in the age segments
of 30-34 years (10.82 percent) and 35-39 years (8.03 percent) had the highest
infection rates and also were the groups with the highest prevalence of
CIN2/3, thus reinforcing the clinical benefit of reserving routine HPV testing
for women age 30 and higher.

"These study results illustrate the benefits to large health systems of
combined screening with the digene HPV Test and a Pap for all women age 30 and
older, and dispels the notion that excessive numbers of women would require
increased surveillance and follow-up when HPV testing is implemented," said
Dr. Jim Godsey, Senior Vice President Research & Development North America for
QIAGEN. "Some doctors have exercised caution using HPV testing out of
now-disproven concern that they would have a lot of patients with Pap
normal/HPV positive test results who would require counseling and follow-up.
This study clearly demonstrates that this is not the case, and importantly
shows cotest outcome rates within the very large and diverse patient
population that Kaiser serves. This is good news to the clinical community who
may have been overly anxious about the management of a large number of HPV
positive, Pap normal test results. In fact, by identifying the women who test
positive for infection with one of the cancer causing types of HPV -- and who
are hence at greater risk of developing cervical disease -- clinicians can
more effectively direct treatment and follow-up, potentially detecting more
early stage disease and saving lives."

Kaiser Permanente Northern California performs HPV testing with the digene HPV
Test and provides Pap and HPV cotesting to its female patients age 30 and
older to better identify those at risk of developing cervical cancer. The
digene HPV Test detects the presence of high-risk types of HPV, the primary
cause of cervical cancer. The test is recommended for use along with the Pap
to screen women age 30 and older, the group most at risk of developing
cervical cancer, as well as for follow-up evaluation in women whose Pap
results are inconclusive.

"We recognize that women who test positive for carcinogenic HPV and negative
by cytology are at an elevated risk for cervical pre-cancer and cancer
compared with women who test negative on both," the study authors write,
suggesting that future clinical research will need to focus on identifying
"the best strategies for managing women who test positive for carcinogenic HPV
and negative by cytology."

While the Pap test relies on a laboratory technician to manually look for cell
changes that may signal cervical disease, QIAGEN's digene HPV Test, which uses
the company's proprietary Hybrid Capture 2 (hc2) technology, uses advanced
molecular technology to identify the presence of the genetic code (DNA) of 13
high-risk, cancer causing types of HPV. More than 40 million tests for
carcinogenic HPV have been performed with the digene HPV Test. FDA-approved
since 1999, the digene HPV Test has been published in more than 300
peer-reviewed journal articles and studied in clinical trials involving more
than 825,000 women worldwide. It is quickly becoming a new standard-of-care
for cervical cancer screening and is recognized as the "gold-standard" in HPV
testing.

About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading global provider of
sample and assay technologies. Sample technologies are used to isolate and
process DNA, RNA and proteins from biological samples such as blood or tissue.
Assay technologies are used to make such isolated biomolecules visible. QIAGEN
has developed and markets more than 500 sample and assay products as well as
automated solutions for such consumables. The company provides its products to
molecular diagnostics laboratories, academic researchers, pharmaceutical and
biotechnology companies, and applied testing customers for purposes such as
forensics, animal or food testing and pharmaceutical process control. QIAGEN's
assay technologies include one of the broadest panels of molecular diagnostic
tests available worldwide. This panel includes the leading FDA-approved test
for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN
employs more than 3,000 people in over 30 locations worldwide. Further
information about QIAGEN can be found at http://www.qiagen.com/.

SOURCE QIAGEN

In Europe, Thomas Theuringer, +49-2103-29-11826 or in Americas, Shelley
Ducker, +1-240-686-7603, both for QIAGEN, pr@qiagen.com; Investor Relations,
ir@qiagen.com, in Europe, Solveigh Maehler, +49-2103-29-11710 or in Americas,
Al Fleury, +1-301-944-7028